Biothera unveils updated data from Phase 2 mTNBC trial at SABCS
Category: #health  By Mateen Dalal  Date: 2019-12-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biothera unveils updated data from Phase 2 mTNBC trial at SABCS

Biothera Pharmaceuticals, Inc., a renowned Minnesota based biotechnology company, reportedly announced that clinical benefit data and updated response from its Phase 2 study in chemo-refractory mTNBC (metastatic triple negative breast cancer) patients would be presented in a Spotlight Session during the 2019 San Antonio Breast Cancer Symposium (SABCS).

The Phase 2 study evaluates Biothera’s Imprime PGG, which is a systematically delivered dectin receptor triggering anti-cancer immune responses, with the anti-PD-1 therapy developed by Merck, KEYTRUDA® (pembrolizumab). The participants of the study were not treated earlier using immune checkpoint inhibitors. They also were identified as positive biomarker for Imprime PGG therapy.

Jeremy Graff, Ph.D., President and Chief Scientific Officer, Biothera Pharmaceuticals, reportedly stated that the clinical data showed compelling evidence from the combination of KEYTRUDA and Imprime PGG in chemo refractory mTNBC patients. Graff further added that the translational data not just delivers proof of concept at the cellular and molecular level, but also offers valuable insights regarding the next steps for clinical development of Imprime PGG.

Latest data from IMPRIME 1 showcased at SABCS depicted 15.9% overall response rate in mTNBC patients that were treated with the combination of KEYTRUDA and Imprime PGG.

Most of the patients showed target lesion stabilization or reduction. The discontinuation of treatment frequently resulted from increase in non-target lesion or new lesions, even when target lesions were stable or shrinking. Patients with such mixed response pattern showed an overall increase in survival.
 

About Biothera Pharmaceuticals:

Biothera Pharmaceuticals is a renowned biotechnology company headquartered in Minnesota. The firm is committed in developing CPIs, or immune checkpoint inhibitors in combination with Imprime PGG in multiple Phase 2 cancer indications. Its focus is on population of patients and types of tumor wherein single agent CPI therapy provides limited benefits. The types of tumor include non-small cell lung cancer, metastatic triple negative breast cancer, CPI-failed advanced melanoma and colorectal cancer.

 

Source credit: https://www.biothera.com/biothera-pharmaceuticals-presents-updated-phase-2-data-for-chemo-refractory-triple-negative-breast-cancer-patients-at-san-antonio-breast-cancer-symposium/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...

Adevinta Ventures backs Lovys's Series A follow-on investment round
Adevinta Ventures backs Lovys's Series A follow-on investment round
By Mateen Dalal

Adevinta Ventures, an investment arm of Adevinta, has announced its investment in French insurance service provider ‘Lovys’, marking as its first investment in France in the Fintech and Insurtech sector. With this investment, Adevinta Ve...

Indian EV startup eBikeGo expands fleet to 2,100, hires 70 employees
Indian EV startup eBikeGo expands fleet to 2,100, hires 70 employees
By Mateen Dalal

The company is aiming for achieving a 2% share in the Indian electric two-wheeler market, with plans to deploy 200,000 e-scooters across 100 cities eBikeGo, an electric vehicle startup, has recently revealed that it has increased its fleet of electr...